Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

LCI-LUN-NSC-SBRT-001: Phase II Prospective Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non-Small Cell Lung Cancer

This is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and treated with Stereotactic Body Radiation Therapy (SBRT) followed by concurrent mediastinal chemoradiation with or without consolidation chemotherapy. A total of 60 subjects will be enrolled to this study over a 4 year accrual period.

Study Overview

• Status: Active, not recruiting
• Conditions: Non Small Cell Lung Cancer; Lung Cancer Stage III; Lung Cancer Stage II
• Intervention / Treatment: Radiation: SBRT; Drug: Carboplatin; Drug: Paclitaxel; Drug: cis Platinum; Drug: Etoposide; Radiation: IMRT; Drug: Durvalumab

Detailed Description

This study's primary objective is to assess the efficacy of a treatment regimen involving Stereotactic Body Radiation Therapy (SBRT) delivered to the primary tumor followed by concurrent mediastinal chemoradiation by evaluating the proportion of subjects with locally-advanced non-small cell lung cancer (NSCLC) stage II/III who are alive and progression free at 12 months, and to compare to relevant historical controls. Additionally, the treatment regimen will be evaluated based on progression free survival, overall survival, radiologic clinical complete response rate following completion of therapy, objective response rate as defined by RECIST v 1.1, local and locoregional control, patterns of failure, and quality of life. Safety objectives include the rate of grade 2+ radiation pneumonitis and grade 3+ pulmonary events. Exploratory objectives include differential expression of cytokines and chemokines associated with radiation therapy will be determined.

• Study Type: Interventional
• Enrollment (Actual): 61
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • North Carolina
    • Charlotte, North Carolina, United States, 28204
      • Levine Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

Subjects must meet all the following criteria:

• Histologic or cytologic documentation of NSCLC (all histologies allowed)
• Stage II or III disease (AJCC 7th Edition) based on imaging as required during screening: Stage II disease includes only subjects with medically inoperable N1 disease otherwise meeting eligibility criteria. Primary tumor ≤ 7 cm
• Subjects with non-malignant pleural effusion identified on CT scan are eligible provided the effusion is not known or demonstrated to be an exudative effusion. If a pleural effusion is present, the following criteria must be met to exclude malignant involvement: A pleuracentesis is required if pleural fluid is present and visible on both CT scan and chest x-ray. Pleural fluid cytology must be negative for malignancy. Effusions that are minimal and too small for pleuracentesis as determined by the investigator will be eligible for enrollment.
• FEV1 ≥ 1.0 Liter or ≥ 40% predicted with or without bronchodilator within six months prior to initiation of study treatment. Subjects who meet the criterion without O2, but who need acute (started within 10 days prior to enrollment) supplemental oxygen due to tumor-caused obstruction/hypoxia are eligible, provided the amount of the O2 needed has been stable.
• Age ≥18 years.
• ECOG performance status ≤ 2
• Subjects must have normal organ and marrow function as defined: Leukocytes ≥4,000/mcL; Absolute neutrophil count ≥1,500/mcL; Platelets ≥100,000/mcL; Total bilirubin ≤1.5 times the upper limit of normal; Creatinine clearance ≥25 mL/min/1.73 m2
• Negative serum or urine pregnancy test prior to enrollment for women of childbearing age and potential.
• The effects of radiation on the developing human fetus are not well described. For this reason, women of child-bearing potential and non-sterilized men who are sexually active with a woman of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
• Must be considered a candidate for durvalumab, per the treating investigator
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Subjects must not meet any of the following criteria.

• Subjects who have had prior systemic therapy for lung cancer
• Subjects who have had prior radiation to the region of the chest that would result in overlap of radiation therapy fields and determined by the treating physician to impede the treatment of the study malignancy.
• Subjects who are actively being treated on any other interventional research study.
• Prior invasive malignancy unless disease free for a minimum of 3 years from enrollment. However, non-melanoma skin cancer, low risk prostate cancer, well differentiated thyroid cancers, in situ carcinomas of the breast, oral cavity, cervix, and other organs, and tumors that are not thought to impact the life expectancy of the subject according to the treating investigator is permissible.
• Centrally located primary tumor < 2 cm from involved nodal disease which would result in significant overlap of radiation dose. Centrally located is defined as within or touching the zone of the proximal bronchial tree, which is a volume 2 cm in all directions around the proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus right and left lower lobe bronchi).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Single Arm; SBRT + Concurrent Mediastinal Chemoradiation +/- Consolidation Chemotherapy/Adjuvant Immunotherapy	Radiation: SBRT; Primary tumor SBRT; Drug: Carboplatin; concurrent chemotherapy; Drug: Paclitaxel; concurrent chemotherapy; Drug: cis Platinum; concurrent chemotherapy; Drug: Etoposide; concurrent chemotherapy; Radiation: IMRT; mediastinal radiation; Drug: Durvalumab; adjuvant immunotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
12-Month Progression Free Survival	Progression-free survival (PFS) will be determined for each subject as a binary variable indicating whether or not the subject is alive and progression free at 12 months	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free Survival	Progression free survival (PFS) is defined as the duration of time from enrollment to the study to first occurrence of either progressive disease or death.	5 years
Overall survival (OS)	Overall survival (OS) is defined as the duration of time from the date of enrollment to the study to the date of death from any cause.	5 years
Radiologic clinical complete response	Radiologic clinical complete response will be recorded for each subject as a binary variable indicating whether or not the subject had no evidence of disease on PET/CT or CT scan approximately 3 months after the last treatment of concurrent mediastinal chemoradiation.	3 months
Objective Response	Objective response will be determined for each subject as a binary variable indicating whether or not the subject achieved a best overall response of Complete Response (CR) or Partial Response (PR).	3 months
Local Control	Local control (LC) is defined as the duration of time from enrollment to the study to first progression of the subject's primary lesions(s).	12 and 24 months
Regional Control	Regional control (RC) is defined as the duration of time from enrollment to the study to first progression of the subject's regional lesion(s).	12 and 24 months
Locoregional Control	Locoregional control is defined as the duration of time from enrollment to the study to first progression of the subject's local and/or regional lesion(s), whichever occurs first.	12 and 24 months
Distant Control	Distant control defined as the duration of time from enrollment to the study to first metastatic progression.	12 and 24 months
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Score	The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms.	pre-SBRT, post-SBRT/pre-chemoradiation, and 1, 3, 6, and 12 months after the last treatment of chemoradiation
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer Module 13 (EORTC QLQ-LC13) Score	The QLQ-LC13 includes questions assessing lung cancer associated symptoms, treatment related side effects and pain medication. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score represents a higher (better) level of functioning, or a higher (worse) level of symptoms.	pre-SBRT, post-SBRT/pre-chemoradiation, and 1, 3, 6, and 12 months after the last treatment of chemoradiation
Change from Baseline in MD Anderson Symptom Inventory - Lung Cancer (MDASI-LC) Score	The MDASI-LC Module includes 22 questions to assess the severity of multiple lung cancer-related symptoms and the impact of these symptoms on daily functioning. Scores for each item range from 0 to 10, where 0 indicates no symptoms and 10 indicates worst possible symptoms.	pre-SBRT, post-SBRT/pre-chemoradiation, and 1, 3, 6, and 12 months after the last treatment of chemoradiation

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Grade 2 or higher adverse events of special interest	Toxicities will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Toxicities will be tabulated by type and grade separately for each phase of treatment.	up to 6 months post-SBRT

Collaborators and Investigators

• Sponsor: Wake Forest University Health Sciences
• Collaborators: AstraZeneca; Atrium Health Levine Cancer Institute
• Investigators: Principal Investigator: John H Heinzerling, Wake Forest University Health Sciences

Study record dates

Study Major Dates

• Study Start (Actual): May 12, 2017
• Primary Completion (Actual): July 12, 2023
• Study Completion (Estimated): July 1, 2027

Study Registration Dates

• First Submitted: May 3, 2017
• First Submitted That Met QC Criteria: May 3, 2017
• First Posted (Actual): May 5, 2017

Study Record Updates

• Last Update Posted (Estimated): April 15, 2024
• Last Update Submitted That Met QC Criteria: April 11, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Chemoradiation; Immunotherapy; Stereotactic body radiation
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antineoplastic Agents, Immunological; Carboplatin; Etoposide; Paclitaxel; Cisplatin; Durvalumab
• Other Study ID Numbers: IRB00081382; 00021247 (Other Identifier: Advarra IRB); LCI-LUN-NSC-SBRT-001 (Other Identifier: Atrium)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No